CTRI/2019/11/021844尚未招募4 期
Efficacy and safety of Diosmin (900 mg) given along with Tranexamic acid (500 mg) and Mefenamic acid (250 mg) in reducing menstural blood loss in patients of Abnormal Uterine Bleeding A Prospective double blind randomized controlled trial(RCT) - NI
Walter Bushnell Pvt ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •all womwn of reproductive age group between 18 to 45 years of age having abnormal uterine bleeding of only non structural cause and those willing to participate will be included in the study
排除标准
- •1. Patients with a history of recent IUCD
- •or hormonal therapy,
- •2. Anovulatory or irregular cycles,
- •3. Pregnancy or any pelvic pathology,
- •4. Coagulation disturbances
- •5. Polycystic ovarian disease
- •6. Thyroid, liver or renal Abnormal.
- •7. Women not willing to participate in the
研究者
相似试验
已完成
4 期
Effectiveness and safety of a mixture of diosmin, coumarin and arbutin (Linfadren®) in addition to conventional treatment, in the management of patients with persistent hand edema following trauma or surgery of distal forearm or hand. A randomized controlled trial.persistent hand edema following trauma or surgery of distal forearm or handACTRN12618001033235Angelo Cacchio60
进行中（未招募）
1 期
A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European population.EUCTR2011-000045-20-ESRECORDATI S.p.A
进行中（未招募）
1 期
Effectiveness and safety of silodosin in the treatment of patients with benign prostatic hyperplasia.Benign prostatic hyperplasia.EUCTR2011-000045-20-RORECORDATI S.p.A
进行中（未招募）
不适用
Effectiveness and safety of silodosin in the treatment of LUTS in patients with benign prostatic hyperplasia: a European phase IV clinical study (the Silodosin in Real-life Evaluation study) - SIREBenign prostatic hyperplasia.MedDRA version: 13.1Level: PTClassification code 10004446Term: Benign prostatic hyperplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-000045-20-HURECORDATI S.p.A1,000
进行中（未招募）
不适用
A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European population.EUCTR2011-000045-20-PTRECORDATI S.p.A1,000